Contribution of extracellular signal-regulated kinase to angiotensin II-induced transforming growth factor-β1 expression in vascular smooth muscle cells

被引:53
作者
Hamaguchi, A [1 ]
Kim, S [1 ]
Izumi, Y [1 ]
Zhan, YM [1 ]
Yamanaka, S [1 ]
Iwao, H [1 ]
机构
[1] Osaka City Univ, Sch Med, Dept Pharmacol, Abeno Ku, Osaka 5458585, Japan
关键词
muscle; smooth; vascular; angiotensin II; transforming growth factor beta; protein kinases; oligonucleotides; antisense;
D O I
10.1161/01.HYP.34.1.126
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
We have previously demonstrated that angiotensin II (Ang II) contributes to the increase in aortic transforming growth factor-beta(1) (TGF-beta(1)) mRNA levers in hypertensive rats. However, the molecular mechanism whereby Ang II promotes,TGF-beta(1) expression in vascular smooth muscle cells (VSMCs) is poorly understood. Tn this study, we examined the role of extracellular signal-regulated kinase (ERK) in Ang II-mediated TGF-beta(1) expression in VSMCs and the role of Ang II in aortic ERK activity of stroke-prone spontaneously hypertensive rats. Treatment of quiescent VSMCs with 100 nmol/L Ang II induced rapid phosphorylation and activation of ERK1 and ERK2 with a peak at 5 minutes followed by an increase in activator protein-1 (AP-1) DNA binding activity, as shown by gel mobility shift assay. An increase in TGF-beta(1) mRNA was shown by Northern blot analysis. Treatment of VSMCs with PD98059, a specific inhibitor of the ERK pathway, attenuated both the activation of-AP-1 and the increase in TGF-beta(1) mRNA induced by Ang II. Inhibition of Ang II-induced AP-1 activation with c-fos antisense oligodeoxynucleolide led to a significant reduction of TGF-beta 1 mRNA in VSMCs. Furthermore, in vivo treatment of stroke-prone spontaneously hypertensive rats with losartan, an Ang II type 1 receptor antagonist decreased aortic ERK activity Thus, we shaw that ERK, through AP-1 activation, is involved in Ang II-induced TGF-beta(1) mRNA expression in VSMCs and suggest that ERK may participate in vascular remodeling of hypertension. However, it remains to be determined whether the increase in TGF-beta(1) mRNA leads to the increase in its active protein.
引用
收藏
页码:126 / 131
页数:6
相关论文
共 29 条
  • [21] ANGIOTENSIN-II TYPE-1 RECEPTOR BLOCKADE INHIBITS THE EXPRESSION OF IMMEDIATE-EARLY GENES AND FIBRONECTIN IN RAT INJURED ARTERY
    KIM, SK
    KAWAMURA, M
    WANIBUCHI, H
    OHTA, K
    HAMAGUCHI, A
    OMURA, T
    YUKIMURA, T
    MIURA, K
    IWAO, H
    [J]. CIRCULATION, 1995, 92 (01) : 88 - 95
  • [22] ROLE OF ANGIOTENSIN-II IN EXTRACELLULAR-MATRIX AND TRANSFORMING GROWTH-FACTOR-BETA-1 EXPRESSION IN HYPERTENSIVE RATS
    OHTA, K
    KIM, S
    HAMAGUCHI, A
    YUKIMURA, T
    MIURA, K
    TAKAORI, K
    IWAO, H
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1994, 269 (01): : 115 - 119
  • [23] TRANSFORMING GROWTH FACTOR-BETA-INDUCED GROWTH-INHIBITION AND CELLULAR HYPERTROPHY IN CULTURED VASCULAR SMOOTH-MUSCLE CELLS
    OWENS, GK
    GEISTERFER, AAT
    YANG, YWH
    KOMORIYA, A
    [J]. JOURNAL OF CELL BIOLOGY, 1988, 107 (02) : 771 - 780
  • [24] CDNA CLONING BY PCR OF RAT TRANSFORMING GROWTH-FACTOR BETA-1
    QIAN, SW
    KONDAIAH, P
    ROBERTS, AB
    SPORN, MB
    [J]. NUCLEIC ACIDS RESEARCH, 1990, 18 (10) : 3059 - 3059
  • [25] Inhibition of growth factor-induced protein synthesis by a selective MEK inhibitor in aortic smooth muscle cells
    Servant, MJ
    Giasson, E
    Meloche, S
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (27) : 16047 - 16052
  • [26] TAUBMAN MB, 1989, J BIOL CHEM, V264, P526
  • [27] TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205
  • [28] ANGIOTENSIN-II STIMULATES 2 MYELIN BASIC-PROTEIN MICROTUBULE ASSOCIATED PROTEIN-2 KINASES IN CULTURED VASCULAR SMOOTH-MUSCLE CELLS
    TSUDA, T
    KAWAHARA, Y
    ISHIDA, Y
    KOIDE, M
    SHII, K
    YOKOYAMA, M
    [J]. CIRCULATION RESEARCH, 1992, 71 (03) : 620 - 630
  • [29] ANTIBODIES AGAINST TRANSFORMING GROWTH-FACTOR-BETA-1 SUPPRESS INTIMAL HYPERPLASIA IN A RAT MODEL
    WOLF, YG
    RASMUSSEN, LM
    RUOSLAHTI, E
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (03) : 1172 - 1178